Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3Other solid neoplasm 3Genitourinary 2Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 577Triple Negative Breast Neoplasms 125Neoplasm Metastasis 50Breast Neoplasms, Male 28Ovarian Neoplasms 26Neoplasms 26Inflammatory Breast Neoplasms 22Carcinoma, Non-Small-Cell Lung 19Stomach Neoplasms 14Endometrial Neoplasms 11Carcinoma, Ductal, Breast 11Carcinoma, Ovarian Epithelial 10Pancreatic Neoplasms 9Colorectal Neoplasms 9Melanoma 8Lung Neoplasms 8Parkinson Disease 4, Autosomal Dominant Lewy Body 7HER2-positive Breast Cancer 7Squamous Cell Carcinoma of Head and Neck 6Prostatic Neoplasms 6Esophageal Neoplasms 6Carcinoma, Renal Cell 6Uterine Cervical Neoplasms 5Urinary Bladder Neoplasms 4Brain Neoplasms 4Anatomic Stage I Breast Cancer AJCC v8 4Advanced Breast Cancer 4Small Cell Lung Carcinoma 3Sarcoma 3Recurrence 3

Interventions

pembrolizumab 9Nivolumab 4budigalimab 2belinostat 2Pemetrexed 2Ipilimumab 2Cyclophosphamide 2Cisplatin 2Carboplatin 2venetoclax 1tocilizumab 1tislelizumab 1talazoparib 1spartalizumab 1rovalpituzumab tesirine 1ribociclib 1rebastinib 1obinutuzumab 1naptumomab estafenatox 1fludarabine 1epacadostat 1enzalutamide 1durvalumab 1cabozantinib 1abemaciclib 1Valacyclovir 1Sorafenib 1Sirolimus 1Quality of Life 1Plicamycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesothelioma × Paclitaxel × Breast × Clear all
NCT02071862 2022-07-20

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Calithera Biosciences, Inc

Phase 1 Completed
210 enrolled
BreastGenitourinaryOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Mesothelioma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡